• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EPOETIN ALFA Drug Record

  • Summary
  • Interactions
  • Claims
  • EPOETIN ALFA chembl:CHEMBL1201565 Approved

    Alternate Names:

    EPOETIN ALFA
    EPREX
    EPO
    EPOGEN
    PROCRIT
    BINOCRIT
    ERYTHROPOIETIN PRECURSOR
    chemidplus:113427-24-0
    chembl:CHEMBL1201565
    drugbank:00016
    rxcui:105694

    Drug Info:

    (0 More Sources)

    Publications:

    Pawlak et al., 2006, Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients., Am. J. Nephrol.
    Kanaan et al., 2006, Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease., Brain Res.
    Kirito et al., 1997, A distinct function of STAT proteins in erythropoietin signal transduction., J. Biol. Chem.
    Ozisik et al., 2006, Expression of antiapoptotic survivin and aven genes in rat heart tissue after traumatic brain injury., Transplant. Proc.
    Krosl et al., 1996, Interleukin-3 (IL-3) inhibits erythropoietin-induced differentiation in Ba/F3 cells via the IL-3 receptor alpha subunit., J. Biol. Chem.
    Reems et al., 1997, Differential modulation of adhesion markers with ex vivo expansion of human umbilical CD34+ progenitor cells., Biol. Blood Marrow Transplant.
    Park et al., 2006, ERK-mediated production of neurotrophic factors by astrocytes promotes neuronal stem cell differentiation by erythropoietin., Biochem. Biophys. Res. Commun.
    Baj et al., 1992, T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment., Arch. Immunol. Ther. Exp. (Warsz.)
    Xu et al., 2005, Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB., Ann. Clin. Lab. Sci.
    Savino et al., 2006, Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis., J. Neuroimmunol.
    Liang et al., 1997, Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure., Nephrol. Dial. Transplant.
    Imagawa et al., 1997, Negative regulation of the erythropoietin gene expression by the GATA transcription factors., Blood
    Imagawa et al., 1996, GATA transcription factors negatively regulate erythropoietin gene expression., Acta Haematol.
    Machide et al., 1995, Interleukin 3 and erythropoietin induce association of Vav with Tec kinase through Tec homology domain., Oncogene
    Hochachka et al., 2003, Fine tuning the HIF-1 'global' O2 sensor for hypobaric hypoxia in Andean high-altitude natives., Bioessays
    Wiesener et al., 2002, Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma., Blood
    Osada et al., 2002, NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1., J. Biol. Chem.
    Carta et al., 2000, Erythropoietin-dependent suppression of the expression of the beta subunits of the interleukin-3 receptor during erythroid differentiation., Blood Cells Mol. Dis.
    Jegalian et al., 2002, Differential roles of SOCS family members in EpoR signal transduction., J. Interferon Cytokine Res.
    Winteringham et al., 2004, Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27Kip1 accumulation., Oncogene
  • EPOETIN ALFA   CISH

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12396724


    Sources:
    NCI

  • EPOETIN ALFA   VAV1

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7651724


    Sources:
    NCI

  • EPOETIN ALFA   CCL4

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17119331


    Sources:
    NCI

  • EPOETIN ALFA   GATA2

    Interaction Score: 2.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9028967 8677751


    Sources:
    NCI

  • EPOETIN ALFA   STAT5B

    Interaction Score: 2.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9195960


    Sources:
    NCI

  • EPOETIN ALFA   IL3RA

    Interaction Score: 1.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8910323


    Sources:
    NCI

  • EPOETIN ALFA   IL1R1

    Interaction Score: 1.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16337691


    Sources:
    NCI

  • EPOETIN ALFA   CDKN1B

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15122318


    Sources:
    NCI

  • EPOETIN ALFA   EPOR

    Interaction Score: 0.46

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Erythropoietin receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • EPOETIN ALFA   TH

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16368081


    Sources:
    NCI

  • EPOETIN ALFA   NTF3

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16337149


    Sources:
    NCI

  • EPOETIN ALFA   ITGAL

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9310190


    Sources:
    NCI

  • EPOETIN ALFA   FCGR3B

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1300984


    Sources:
    NCI

  • EPOETIN ALFA   LDLR

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9249773


    Sources:
    NCI

  • EPOETIN ALFA   CA2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11112384


    Sources:
    NCI

  • EPOETIN ALFA   FCGR3A

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1300984


    Sources:
    NCI

  • EPOETIN ALFA   HSPA4

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15943180


    Sources:
    NCI

  • EPOETIN ALFA   BIRC5

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17112829


    Sources:
    NCI

  • EPOETIN ALFA   HIF1A

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12717822 11986208 11971899


    Sources:
    NCI

  • NCI: EPO

    • Version: 14-September-2017

    Alternate Names:
    C2695 NCI drug code

    Drug Info:

    Publications:
    Ozisik et al., 2006, Expression of antiapoptotic survivin and aven genes in rat heart tissue after traumatic brain injury., Transplant. Proc.
    Krosl et al., 1996, Interleukin-3 (IL-3) inhibits erythropoietin-induced differentiation in Ba/F3 cells via the IL-3 receptor alpha subunit., J. Biol. Chem.
    Reems et al., 1997, Differential modulation of adhesion markers with ex vivo expansion of human umbilical CD34+ progenitor cells., Biol. Blood Marrow Transplant.

  • ChemblDrugs: chembl:CHEMBL1201565

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201565

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21